In this article, we will look at the 10 High Growth International Stocks to Buy Now.

​On February 10, Peter Boockvar, Chief Investment Officer at BFG Wealth Partners, appeared on a CNBC television interview. He said that the weakness in the US dollar is one of the major catalysts boosting the performance of global stocks. Peter noted that the first half of 2025 was the worst in terms of dollar weakness since the early 70s. Moreover, the oversaturation in the “Magnificent Seven” also paved the way for investors to look at international markets. Peter added that the investors also realized that the technology play is not just restricted to the US stock market, and other markets are also experiencing strong earnings growth.

​While elaborating on the catalysts driving international markets, Peter highlighted that trade and tariff wars were also contributing factors. He added that tariffs served as a wake-up call for many international markets to adopt growth-conducive policies. This has resulted in a surge in trade deals between other markets, regulatory policies, and a reduction in red tape across Europe, China, India, and elsewhere. Peter believes there are plenty of attractive opportunities to invest outside the US.

​With that, let’s take a look at the 10 High-Growth International Stocks to Buy Now.

​Our Methodology

To shortlist 10 High Growth International Stocks to Buy Now, we used the Finviz stock screener, Seeking Alpha, and Insider Monkey’s Q3 2025 hedge funds database. Using the screener, we aggregated a list of Ex-USA stocks with more than 25% revenue growth over the past 3 years. Next, we cross-checked the revenue growth from Seeking Alpha and ranked the stocks in ascending order of the number of hedge fund holders.

Why are we interested in the stocks that hedge funds pile into? The reason is simple: our research has shown that we can outperform the market by imitating the top stock picks of the best hedge funds. Our quarterly newsletter’s strategy selects 14 small-cap and large-cap stocks every quarter and has returned 427.7% since May 2014, beating its benchmark by 264 percentage points (see more details here).

​10 High Growth International Stocks to Buy Now

​10. Genmab A/S (NASDAQ:GMAB)

Number of Hedge Fund Holders: 20

​Genmab A/S (NASDAQ:GMAB) is one of the High Growth International Stocks to Buy Now. On January 28, H.C. Wainwright reiterated a Buy rating on Genmab A/S (NASDAQ:GMAB) and maintained a $39 price target. The rating follows robust net sales of DARZALEX in 2025.

​The company on January 21 reported a significant increase in net sales of DARZALEX in 2025. Worldwide net sales of DARZALEX reached $14.351 billion in 2025, up from $11.670 billion in 2024. More than half of the worldwide sales (around $8.266 billion) came from the US, while the remaining $6.085 billion came from the rest of the world.

​Genmab does not sell the drug directly. Instead, they have licensed it exclusively to Johnson & Johnson and earn royalties on all worldwide net sales. During the first nine months of 2025 (ending September 30, 2025), Genmab A/S (NASDAQ:GMAB) received $2.219 billion in total Royalty revenue, which was up significantly from $1.802 billion in the first nine months of 2024. Management attributed the 23% year-over-year increase to higher net sales of DARZALEX and Kesimpta.

​Before Johnson & Johnson reported net sales, management was anticipating full-year DARZALEX royalties to be in the range of $2.3 billion – $2.4 billion. This estimation was based on DARZALEX 2025 net sales of $13.7 billion – $14.1 billion. Since the actual net sales ($14.351 billion) exceed the top end of management’s guidance, the royalties are also expected to surpass the $2.4 billion mark.

​Genmab A/S (NASDAQ:GMAB) is a Denmark-based biotechnology company that specializes in creating and developing antibody therapeutics, primarily for cancer treatment. The company co-developed blockbuster drugs like DARZALEX (for multiple myeloma), Kesimpta (for multiple sclerosis), and TEPEZZA (for thyroid eye disease), earning royalties through licenses to partners like Johnson & Johnson.

​9. BeOne Medicines AG (NASDAQ:ONC)

Number of Hedge Fund Holders: 21

BeOne Medicines AG (NASDAQ:ONC) is one of the High Growth International Stocks to Buy Now. On February 9, Rebecca Liang from Bernstein reiterated a Buy rating on the stock with a $414 price target. Earlier, on February 4, Barclays also reiterated a Buy rating on BeOne Medicines AG (NASDAQ:ONC) and raised the price target from $385 to $394.

​The bullish sentiment follows the first-in-world approval of BeOne’s Sonrotoclax in China to treat adults with two hard-to-treat blood cancers. These include relapsed/refractory mantle cell lymphoma (MCL) and relapsed/refractory chronic lymphocytic leukemia (CLL). The approval in China was based on the MCL study and CLL/SLL study presented at the 2025 ASH conference.

​The MCL study demonstrated 52.4% overall response rate per independent review, and the CLL/SLL study showed 77% ORR per independent review. Management noted that the approval in China is part of a global rollout strategy.

Rebecca Liang from Bernstein believes BeOne Medicines AG (NASDAQ:ONC) to be undervalued considering its pipeline. She noted that “the pipeline is not recognized by the market,” and highlighted Sonrotoclax as “potential best-in-class status.”

​BeOne Medicines AG (NASDAQ:ONC), based in Switzerland,  is a global oncology company focused on discovering and developing innovative cancer treatments for hematology and solid tumors worldwide.